---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-036518"
form_type: "8-K"
ticker: "PLSH"
cik: "0001552189"
company_name: "PANACEA LIFE SCIENCES HOLDINGS, INC."
filed_at: "2022-12-27T23:59:59+00:00"
generated_at: "2026-06-20T22:50:26.591672+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Panacea repays $1.11M convertible note; CEO credit line raised to $5M

## Summary
- Repaid $1,110,306.85 on Dec 21, 2022 to retire a 10% OID senior convertible note issued Nov 2021.
- Original note had $1.1M principal, 10% discount, and warrants for 785,715 shares at $1.40/share.
- Funding came from CEO line of credit, which was amended to increase borrowing capacity to $5M.
- Note maturity was Nov 16, 2022; repayment satisfied all obligations under the Purchase Agreement.

## SEC filing metadata
- accession: 0001493152-22-036518
- form_type: 8-K
- ticker: PLSH
- cik: 0001552189
- company_name: PANACEA LIFE SCIENCES HOLDINGS, INC.
- filed_at: 2022-12-27T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1552189/000149315222036518/0001493152-22-036518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1552189/000149315222036518/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-036518
- JSON: https://secwatch.observer/filing/0001493152-22-036518.json
- Plain text: https://secwatch.observer/filing/0001493152-22-036518.txt

## Key facts
- Material Agreements
  PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Securities Purchase Agreement with an institutional investor valued at $1,000,000 (effective 2021-11-16).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional investor
  - Value: $1,000,000
  - Effective: 2021-11-16
  source text: On November 16, 2021, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) pursuant to which the Company sold a 10% original issue discount senior convertible promissory note in the principal amount of $1,100,000 (the “Note”) and five-year warrants to purchase 785,715 shares of the Company’s common stock, par value $0.0001 per share at an exercise price of $1.40 per share (the “Warrants”) pursuant to the terms and conditions of the SPA for a total purchase price of $1,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1552189/000149315222036518/0001493152-22-036518-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.